Novacyt Reports 2025 Revenue in Line with Expectations
On Tuesday, Novacyt released its unaudited preliminary results for the fiscal year 2025, reporting a statutory revenue of approximately 20.0 million British pounds, consistent with market forecasts. The molecular diagnostics group has maintained consecutive semi-annual growth in its operations while preserving a strong cash position.
Revenue Details and Segment Performance
Novacyt's revenue for the fiscal year ending December 31, 2025, stood at approximately 20.0 million British pounds, up from 19.6 million a year earlier, according to the release. This increase of about 4% (5% at constant exchange rates) does not account for the impact of the divestment of the Taiwan service lab. The clinical sector generated 13.8 million pounds in revenue, up 3%, supported by acquiring a new strategic client in the Asia-Pacific region. Within this segment, non-invasive prenatal testing (NIPT) technologies grew by more than 10% compared to the previous fiscal year. Geographically, the Asia-Pacific region recorded the highest growth with an increase of about 10% and revenue of 5.5 million pounds, driven by demand for reproductive health products. The Americas saw a growth of about 8%, the company indicates.
Instrumentation Sector and Product Developments
The instrumentation sector saw its revenue increase by more than 25% to reach 2.5 million pounds, up from 2.0 million in the fiscal year 2024, according to the group. This performance is primarily due to the launch of the LightBench Discover instrument, a 3-in-1 device intended for genomic research laboratories performing long-read sequencing. Since its launch in July 2025, the company has deployed 10 instruments and established several collaborations. Conversely, the RUO (research only) sector recorded a decrease of about 10% with revenue of 3.7 million pounds, down from 4.2 million the previous year, due to reduced sales from the Primerdesign product catalog. However, in November 2025, the group launched the Primerdesign exsig Mag RapidBead Pro extraction kit. Beta testing is also underway with international opinion leaders for the Yourgene Insight DPYD test, aimed at identifying patients at risk of severe reactions to certain chemotherapies, with a launch planned for the first half of 2026.
Financial Position and Market Expectations
Novacyt has maintained sequential semi-annual growth over three consecutive periods, with revenue increasing from 9.6 million pounds in the second half of 2024 to 10.2 million in the second half of 2025, according to the release. As of December 31, 2025, the group's cash position was 19.2 million pounds, down from 23.8 million on June 30, 2025. The group remains debt-free. Through rigorous cost management, EBITDA losses are expected to meet or exceed market expectations, the company indicates. The board specifies that market expectations for the fiscal year ending December 31, 2025, were for revenue of 19.8 million pounds, an adjusted EBITDA loss of 8.5 million, and a closing cash balance of 18.8 million. The group plans to present its audited annual results in April 2026.
